TRV GP V, LLC
Long book
$401.0M
Q1 2026
Positions
3
Top-10 weight
100%
concentration
Last quarter
+29.5%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsTRV GP V, LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $401.0M US long book across 3 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: RAPPORT THERAPEUTICS INC, SEPTERNA INC, MAZE THERAPEUTICS INC.
Over the last 6 quarters its long book ran on average 19pp per quarter ahead of the S&P 500, beating the index in 4 of 6 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
-60.0%
Q1 2025
+34.3%
Q2 2025
+123.0%
Q3 2025
+21.4%
Q4 2025
-6.6%
Q1 2026
+29.5%
Sector allocation
Healthcare 100%
Long book by quarter
What does TRV GP own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 7, 2026 | 3 | $401.0M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 3 | $429.2M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 3 | $353.5M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 8, 2025 | 4 | $165.7M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 9, 2025 | 4 | $125.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 3 | $294.0M | canonical | SEC ↗ |